Barclays Upgrades Celldex Therapeutics to Overweight, Raises Price Target to $45
Benzinga Newsdesk 6 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Barclays analyst Etzer Darout upgrades Celldex Therapeutics (NASDAQ:CLDX) from Underweight to Overweight and raises the price target from $24 to $45.
Barclays analyst Etzer Darout upgrades Celldex Therapeutics (NASDAQ:CLDX) from Underweight to Overweight and raises the price target from $24 to $45.